Arbutus to present imdusiran data at easl congress 2024

Warminster, pa., may 22, 2024 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis b virus (chbv) infection, today announced that two abstracts have been accepted for poster and oral presentations at the european association for the study of the liver (easl) congress 2024 taking place june 5 - 8, 2024 in milan, italy.
ABUS Ratings Summary
ABUS Quant Ranking